Immunotherapy as part of combinations for the treatment of cancer

This publication has 31 references indexed in Scilit:

• Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope
  Journal of Clinical Oncology, 2002
• Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma
  Journal of Clinical Oncology, 2002
• Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
  The Journal of Experimental Medicine, 2001
• Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
  The Journal of Experimental Medicine, 2001
• The Emerging Role of CTLA-4 as an Immune Attenuator
  Immunity, 1997
• Phase II Trial of Interleukin-2 and Interferon-ce in Patients with Renal Cell Carcinoma: Clinical Results and Immunologic Correlates of Response
  Journal of Immunotherapy, 1997
• Immunotherapy of Established Murine Tumors with Large Multivalent Immunogen and Cyclophosphamide
  Journal of Immunotherapy, 1996
• Antibodies Against Mucin-Associated Sialyl-Tn Epitopes Correlate with Survival of Metastatic Adenocarcinoma Patients Undergoing Active Specific Immunotherapy with Synthetic STn Vaccine
  Journal of Immunotherapy, 1996
• The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies
  European Journal of Cancer and Clinical Oncology, 1991
• Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignancies
  The Lancet, 1990